Pharos iBio said it has signed a memorandum of understanding with MEDiC Life Sciences, a Silicon Valley-based company that has established a gene-scissor technology (CRISPR) based cancer target and biomarker discovery platform, to collaborate on drug discovery.Through this agreement, the two compani
GC Biopharma said it has submitted an investigational new drug (IND) application and applied for Fast Track Designation with the U.S. FDA for GC1130A, an intracerebroventricular (ICV) enzyme replacement therapy (ERT) drug for Sanfilippo Syndrome Type A (MPS IIIA), jointly developed with Korean biote
Celltrion's Remsima (infliximab) line of products continues to demonstrate market impact with expanded prescriptions in five major European countries—the U.K., Germany, France, Spain, and Italy—also known as EU5.According to pharmaceutical market research firm IQVIA, as of the fourth quarter of 2023
HK inno.N's GERD drug K-CAB has expanded its momentum to the Middle East and North Africa region.Starting from China and expanding across Asia and North and South America, K-CAB is increasing its global market dominance by advancing to the Middle East and North Africa markets, according to the compa
Curocell, a chimeric antigen receptor-T (CAR-T) developer, has applied for Anbal-cel, its CAR-T candidate, to be included in the Ministry of Food and Drug Safety (MFDS)’s Advanced Biomedicine Expedited Approval System.The system is designed to facilitate the rapid market entry of innovative medicine
In alignment with Earth Day, an annual event on April 22, Bayer Korea began its annual "Glück for Green" plogging campaign, an initiative designed to foster sustainable practices among its employees. Plogging refers to picking up rubbish while jogging or walkingThis year marks the third installment
Skyrizi (risankizumab) has emerged as a new option for treating palmoplantar pustulosis (PPP), a condition characterized by pustules, exfoliation, and red patches on the palms of the hands and feet that impair quality of life.AbbVie Korea held a media event on Monday to commemorate the approval of i
Korea's largest private equity firm, MBK Partners, has agreed to purchase a majority stake in Geo-Young, the nation's top pharmaceutical distributor, from Blackstone for approximately 1.95 trillion won ($1.4 billion), Seoul Economic Daily said on Monday. This deal marks the largest transaction of it
On Monday, EuBiologics announced that it obtained regulatory approval to initiate a phase 1 study for its proprietary herpes zoster vaccine, EuHZV. With the endorsement from the Ministry of Food and Drug Safety, the company's immune modulation technology has broadened its scope from addressing emerg
Polycythemia vera (PV) is a rare, intractable blood cancer in which a somatic mutation in the bone marrow causes the bone marrow to function abnormally and overproduce red blood cells.The abnormal production of blood cells in the bone marrow causes the blood to become thick, which increases the risk
Four Korean drugmakers have obtained approval for generic versions of Amgen's oral psoriasis treatment, Otezla (apremilast).Daewoong Pharmaceutical, DongKoo Bio&Pharma, Dong-A ST, and Chong Kun Dang will be able to enter the domestic oral psoriasis treatment market abandoned by the original drug.On
Pharmaceutical distribution company Geo-Young said Friday that its consolidated sales for 2023 reached 4.43 trillion won ($3.21 billion).It marked a 5 percent increase from the previous year’s 4.22 trillion won and the largest revenue since its inception. Operating profit for the same period rose 14
Bridge Biotherapeutics, a Korean biotech firm, announced positive feedback from the third Independent Data Monitoring Committee (IDMC) meeting to continue the phase 2 clinical trial of BBT-877, a drug candidate for the treatment of idiopathic pulmonary fibrosis (IPF).IPF is a severe and chronic lung
The drug price negotiations for Pfizer's third-generation ALK-positive lung cancer drug Lorviqua (lorlatinib) are being done in excessive secrecy, leading to growing frustration among patients waiting for its reimbursement.Lorviqua was not on the list of drugs that have completed drug price negotiat
HLB said it opened a new office in the Cambridge Innovation Center (CIC) in Boston, U.S. to bolster the collaboration and communication between HLB and its U.S. subsidiaries, such as Immunomic Therapeutics, while also supporting its group companies' entry into international markets.HLB's new office
The International Nonproprietary Name (INN) of LAPS Glucagon analog (code name HM15136), which Hanmi Pharm is developing as an innovative new drug for treating congenital hyperinsulinemia, has been fixed as “efpegerglucagon.”Hanmi Pharm said Thursday that the World Health Organization has officially
Handok and Swedish Orphan Biovitrum (Sobi) said they have officially inaugurated their Korean joint venture, Handok-Sobi.Sobi is a global biopharmaceutical company specializing in rare diseases, providing innovative treatments in hematology, immunology, and specialized therapies. With 1,800 employee
GC Cell said its U.S. affiliate Artiva Biotherapeutics has begun administering the first dose to a participant in a phase 1 clinical trial. This trial investigates the combination of AlloNK (AB-101) and rituximab as a potential treatment for lupus nephritis.Lupus nephritis is a complication of syste
Celltrion said it has been awarded the national tender for the world's only infliximab subcutaneous (SC) formulation, Remsima SC, in Denmark, a key Nordic market. Under the agreement, Remsima SC will be supplied to Denmark for one year starting this month.Celltrion launched Remsima SC in Norway in F
A clinical study has shown that Orafang tablets are safe for people in their 40s and 50s and for the very elderly aged 70 or more.Pharmbio Korea said Tuesday that it presented clinical results at the Seventh International Meeting on Intestinal Diseases, which was held in conjunction with the Annual